Trials / Completed
CompletedNCT00419887
Safety, Tolerability, Effect of Vildagliptin and How the Body Changes the Blood Level of Vildagliptin in Healthy Chinese Volunteers
A Randomized, Double-Blind, Placebo-Controlled, Time-Lagged, Parallel-Group, Ascending Single and Multiple Oral Dose Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of LAF237 in Chinese Healthy Subjects
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 60 (planned)
- Sponsor
- Novartis · Industry
- Sex
- All
- Age
- 18 Years – 45 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to assess the safety, tolerability, effect of vildagliptin and how the body changes the blood level of vildagliptin of single and multiple oral doses of vildagliptin in healthy Chinese volunteers.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Vildagliptin (LAF237) |
Timeline
- Start date
- 2006-09-01
- First posted
- 2007-01-09
- Last updated
- 2007-06-22
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT00419887. Inclusion in this directory is not an endorsement.